Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 30, 2008

454’s Sequencer and GenomeQuest’s Informatics Tools to Be Offered Together

  • 454 Life Sciences and GenomeQuest inked a comarketing deal allowing GenomeQuest to offer its On-Demand Informatics Service to users of the 454 Genome Sequencer FLX System. GenomeQuest's high-throughput annotation and data-management tools enable rapid characterization of all sequences generated by 454’s Genome Sequencer FLX System.

    This combination improves the speed and convenience in converting the large amounts of sequence data into biologically meaningful information. “Our system's long reads and analysis tools provide rapid de novo assemblies of complex genomes,” notes Chris McLeod, CEO of 454 Life Sciences. “Offering complementary bioinformatics tools enhances our customers' ability to quickly extract biological meaning from their experiments.”

    This comarketing agreement reportedly resulted from extensive pilot activities conducted to evaluate the scientific accuracy and scalability of GenomeQuest's algorithms and informatics platform.

    “When GenomeQuest first proposed to us the ability to computationally screen all of the sequences of an instrument run in one pass to provide annotated reads to our customers, we were hopeful but cautious,” says Edward Szekeres Jr., manager of production informatics at 454. “Ultimately, they exceeded our expectations for each test case.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »